GBIO vs. PBYI, QURE, FHTX, OVID, GTHX, TSVT, OMER, ELYM, PYXS, and ALDX
Should you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include Puma Biotechnology (PBYI), uniQure (QURE), Foghorn Therapeutics (FHTX), Ovid Therapeutics (OVID), G1 Therapeutics (GTHX), 2seventy bio (TSVT), Omeros (OMER), Eliem Therapeutics (ELYM), Pyxis Oncology (PYXS), and Aldeyra Therapeutics (ALDX). These companies are all part of the "pharmaceutical preparations" industry.
Generation Bio (NASDAQ:GBIO) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
Puma Biotechnology has a net margin of 6.79% compared to Generation Bio's net margin of -1,696.87%. Puma Biotechnology's return on equity of 35.49% beat Generation Bio's return on equity.
Puma Biotechnology received 499 more outperform votes than Generation Bio when rated by MarketBeat users. However, 67.86% of users gave Generation Bio an outperform vote while only 66.54% of users gave Puma Biotechnology an outperform vote.
Puma Biotechnology has higher revenue and earnings than Generation Bio. Generation Bio is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Generation Bio had 18 more articles in the media than Puma Biotechnology. MarketBeat recorded 20 mentions for Generation Bio and 2 mentions for Puma Biotechnology. Generation Bio's average media sentiment score of 0.45 beat Puma Biotechnology's score of 0.00 indicating that Generation Bio is being referred to more favorably in the media.
95.2% of Generation Bio shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 21.1% of Generation Bio shares are owned by insiders. Comparatively, 23.7% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Generation Bio has a beta of 2.87, indicating that its stock price is 187% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.
Generation Bio currently has a consensus target price of $8.00, indicating a potential upside of 117.98%. Puma Biotechnology has a consensus target price of $7.00, indicating a potential upside of 49.57%. Given Generation Bio's higher probable upside, equities research analysts clearly believe Generation Bio is more favorable than Puma Biotechnology.
Summary
Puma Biotechnology beats Generation Bio on 10 of the 18 factors compared between the two stocks.
Get Generation Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Generation Bio Competitors List
Related Companies and Tools
